Review Article

The Mechanisms Underlying Chronic Inflammation in Rheumatoid Arthritis from the Perspective of the Epigenetic Landscape

Yasuto Araki1,2 and Toshihide Mimura1,2

1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
2Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

Correspondence should be addressed to Yasuto Araki; arakiya@saitama-med.ac.jp

Received 24 September 2016; Revised 21 November 2016; Accepted 7 December 2016

Academic Editor: Alessandra Santos

Copyright © 2016 Y. Araki and T. Mimura. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that is characterized by synovial hyperplasia and progressive joint destruction. The activation of RA synovial fibroblasts (SFs), also called fibroblast-like synoviocytes (FLS), contributes significantly to perpetuation of the disease. Genetic and environmental factors have been reported to be involved in the etiology of RA but are insufficient to explain it. In recent years, accumulating results have shown the potential role of epigenetic mechanisms, including histone modifications, DNA methylation, and microRNAs, in the development of RA. Epigenetic mechanisms regulate chromatin state and gene transcription without any change in DNA sequence, resulting in the alteration of phenotypes in several cell types, especially RASFs. Epigenetic changes possibly provide RASFs with an activated phenotype. In this paper, we review the roles of epigenetic mechanisms relevant for the progression of RA.

1. Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that results in progressive destruction of articular cartilage and bone and is hard to treat effectively [1]. RA is two- to fourfold more common in women than in men and affects approximately 1% of the world’s population [2]. The pathogenesis of this disease is not yet completely understood as it likely has a complex, multifactorial etiology. Anticitrullinated peptide/protein antibodies (ACPA) were found to be autoantibodies specific for RA [3]. Citrullination is the posttranslational modification of arginine into citrulline by peptidylarginine deiminases (PAD) [4]. Variable citrullinated autoantigens that are recognized by ACPA, such as keratin, filaggrin, fibrin/fibrinogen, vimentin, type II collagen, cartilage oligomeric matrix protein (COMP), and α-enolase, have been identified in RA [5–11]. However, each of these autoantigens is present only in a particular subset of RA patients, suggesting that RA is a syndrome, not a disease. Because citrulline is a nonstandard amino acid, the citrullination of specific antigens could promote the generation of neoepitopes that are recognized by CD4+ T cells in RA patients. Autoreactive CD4+ T cells have been observed in certain animal models, such as adjuvant arthritis in rats [12]. Since CD4+ T cells in RA synovial fluid are oligoclonal, the CD4+ T cell activation process is thought to be antigen driven [13, 14]. However, the oligoclonality of CD4+ T cells has actually been demonstrated in only a few RA patients. Therefore, the role of autoreactive CD4+ T cells in the pathogenesis of RA is not yet entirely convincing. The degree of macrophage infiltration into the synovium is correlated with the degree of bone erosion in the affected joints in RA [15]. CD5+ B cells in the synovium produce nonspecific antibodies, such as IgM/IgG/IgA rheumatoid factors (RF) [16, 17]. This production is induced by interleukin- (IL-) 10 in RA [18]. On the other hand, the production of ACPA requires the help of CD4+ T cells. Thus, it is obvious that macrophages and B cells play an important role in the pathogenesis of RA, but the contribution of CD4+ T cells to their activation is still controversial. The proinflammatory cytokines, such as tumor...
2 Journal of Immunology Research

Mesenchymal stromal or stem cells (MSCs)

Fibroblasts

Synovial fibroblasts (SFs)

(i) Increased capacity to migrate
(ii) Production of proinflammatory cytokines and chemokines
(iii) Production of matrix-degrading enzymes

Epigenetic disorders
(i) Histone modifications
(ii) DNA methylation
(iii) miRNAs

Rheumatoid arthritis synovial fibroblasts (RASFs)

Figure 1: Epigenetic disorders induce the activation of rheumatoid arthritis synovial fibroblasts (RASFs). Normal SFs are differentiated from mesenchymal stromal or stem cells (MSCs) under normal epigenetic regulation in noninflammatory joints of healthy individuals. The activation of SFs is caused by aberrant epigenetic changes in inflammatory joints of RA.

2. The Pathogenesis of RA

2.1. RASFs. The synovial lining layer of joints is two to three cells thick and consists of SFs and synovial macrophages. In RA, the lining layer undergoes dramatic hyperplasia and increases to a density of 10 to 15 cells thick [20, 21]. At the articular borders, the lining layer forms a pannus that invades the adjacent articular cartilage and subchondral bone. The sublining layer has fewer SFs and synovial macrophages in a loose tissue matrix. The sublining layer also undergoes dramatic hyperplasia and is infiltrated with immune cells [22]. Synovial tissues were found to be enriched with memory CD45RO+ T cells, most of which were not activated T cells but rather mature memory T cells that exhibited an enhanced capacity for transendothelial migration [23]. The expression of chemokine receptor C-X-C motif chemokine receptor 4 (CXCR4) was highly expressed in synovial memory T cells [24]. Synovial T cells are thought to be attracted by chemokines and receive survival signals such as IL-7 and IL-15 [25, 26]. Since SFs maintain an activated and aggressive phenotype with a tumor-like behavior in RA, they play a central role in joint destruction and persistent inflammation in RA [27]. RASFs show an increased capacity to migrate and produce matrix-degrading enzymes, such as matrix metalloproteinases (MMPs) and cathepsins, which contribute to cartilage destruction. Their increased proliferation and resistance to apoptosis are controversial [20]. The pannus formation is composed of infiltrating cells, such as monocytes/macrophages, as well as RASFs. RASFs secrete proinflammatory cytokines and chemokines that perpetuate inflammation. In addition, RASFs produce receptor activator of nuclear factor-kappa B ligand (RANKL) and promote osteoclast differentiation, resulting in bone destruction [28].

Understanding the mechanisms underlying the activation of RASFs may lead to the development of the most suitable RA therapy. Recent advances have suggested that not only genetic and environmental factors, but also epigenetic changes, are implicated in the pathogenesis of RA [29, 30]. Mesenchymal stromal or stem cells (MSCs) differentiate into normal SFs under normal epigenetic regulation. The activation of SFs is caused by altered profiles of gene expression that result from epigenetic dysregulation in RA (Figure 1).

2.2. Genetic Factors in RA. Multiple lines of evidence have revealed that genetic factors participate in the etiology of RA. The pairwise concordance rate for RA was 12.3% in monozygotic (MZ) twins and 3.5% in dizygotic (DZ) twins in a Finnish population [31]. Another group showed that the concordance rate for RA was 15.4% in MZ twins and 3.6% in DZ twins in a United Kingdom (UK) population [32]. According to these twin studies, the concordance of MZ twins was higher than that of DZ twins in RA. Analysis of these studies showed that the heritability of RA was 65% in the Finnish group and 53% in the UK group [33]. The genetic contribution was not affected by sex, age, age at onset, or disease severity. A family study demonstrated that the standardized incidence ratio (relative risk [RR]) for RA was 3.02 in the offspring of affected parents, 4.64 in siblings, 9.31 in multiplex families, 6.48 in twins, and 1.17 in spouses [34]. Serological studies reported that susceptibility to RA was associated with certain human leukocyte antigen (HLA-) DRBI alleles that contain conserved five-amino-acid-sequence motifs QKRAA/QRRAA/RRRAA, termed shared...
epitope (SE) [35]. SE-coding HLA-DRB1 alleles include HLA-DRB1*0401, *0404, and *0101 and are associated with RA severity [36]. In addition, SE alleles are strongly associated with the production of ACPA in RA [37]. Candidate gene approaches, genome-wide association studies (GWAS), and trans-ethnic GWAS meta-analyses have identified a number of RA risk genes, such as HLA-DRB1, PTPN22, STAT4, CCR6, TNFAIP3, PAD14, CD40, and FCRL3, many of which are involved in the functions of immune cells, including T cells, B cells, and macrophages [38, 39].

2.3. Environmental Factors in RA. It is undeniable that genetic factors play an important role in the pathogenesis of RA; however, environmental factors also trigger the development of this disease. For example, cigarette smoking influences both the incidence and severity of RA in a dose-dependent fashion and also increases the risk of ACPA production [40]. The RR of RA by cigarette smoking is about 1.8 [41]. However, smokers are subject to the development of periodontitis. Porphyromonas gingivalis is a major causative pathogen of periodontitis and expresses its own unique enzyme, Porphyromonas gingivalis peptidylarginine deiminase (PPAD), which has PAD activity and catalyzes citrullination [42]. The periodontitis-induced citrullination generates autoantigens that drive autoimmunity and induce the production of ACPA in RA [43]. It is possible that smoking-related periodontitis, but not smoking itself, is a direct environmental trigger of the development of RA. On the other hand, smoking has been reported to promote citrullination in the lungs, mediated by PAD enzymes from smoking-activated phagocytes [44, 45]. Smoking associated inflammatory events in the lung are potential environmental triggers for both ACPA production and RA development. Although the precise pathogenic effect of smoking in RA remains unknown, several mechanisms, including periodontitis-induced or lung inflammation-induced citrullination, have been proposed to explain how smoking plays an important role in RA pathogenesis. Molecular mimicry as a result of Epstein-Barr virus (EBV), a ubiquitous virus, may trigger RA [46], as antibodies against the EBV-encoded proteins cross-react with RA-specific proteins [47, 48]. In addition, EBV DNA loads in peripheral blood mononuclear cells, saliva, and synovium increased in RA [49–51]. High numbers of circulating EBV-infected B cells have been observed in RA [52], and EBV-specific T cell function was impaired in this disease [53]. Although several reports have shown aberrant immune responses to EBV in RA, it remains unknown whether these abnormalities are causative. Estrogen enhances the immune response, whereas androgen and progesterone suppress it [54]. Low androgen levels, high estrogen levels, and a reduced ratio of androgen/estrogen have been observed in male and female RA patients, and androgen replacement therapy was shown to improve disease activity in male RA patients [55]. Since vitamin D represses the development of autoimmunity in experimental animal models, it is expected to have immunomodulatory effects [56]. A greater intake of vitamin D reduced the incidence of RA in older women [57]. Exposure to silica through the respiratory tract increased the risk of developing RA [58].

3. Epigenetic Mechanisms

3.1. Chromatin and Epigenetic Mechanisms. In 1942, the British developmental biologist Conrad Hal Waddington first used the term "epigenetics" derived from the Greek word "epigenesis" in his Principles of Embryology textbook. The epigenetic landscape theory that he proposed described a process in which gene regulation (e.g., mutations) modulates development. Recently epigenetics has been defined as "a stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence" [59]. Epigenetic information is transmitted through either mitosis or meiosis.

DNA is highly packaged into chromatin in the nucleus of eukaryotic cells [60]. The basic subunits of the chromatin are nucleosomes consisting of two copies of each of the core histone proteins H2A, H2B, H3, and H4; the DNA wrapped around the core contains 146-147 base pairs. There are two different forms of chromatin structures: (1) euchromatin is an open chromatin structure in which DNA-binding proteins, such as transcription factors (TFs), are accessible to DNA, resulting in active transcription; and (2) heterochromatin is a condensed chromatin structure that lacks accessibility to the transcriptional machinery, resulting in gene silencing.

Several epigenetic mechanisms, including posttranslational histone modifications, DNA methylation, and microRNAs (miRNAs), determine the specific chromatin structure, consequently influencing gene transcription without altering the DNA sequence itself [61]. Chromatin structure in DNA-regulating regions, such as promoters and enhancers, regulates gene transcription by altering the accessibility for TFs.

3.2. Histone Modifications. Covalent posttranslational modifications in histone N-terminal tails, including acetylation, methylation, ubiquitination, and phosphorylation, control the chromatin state and gene transcription [62]. Each modification has specific functions [63, 64]. Active histone markers that are associated with euchromatin and gene activation include acetylation of H2A, H2B, H3 lysine 9 (H3K9), H3K14, H4K5, and H4K16; methylation of H2BK5, H3K4, H3K36, and H3K79; phosphorylation of H3 threonine 3 (H3T3), H3 serine 10 (H3S10), H3S28, and H4S1; and ubiquitination of H2BK120. On the other hand, repressive histone markers that are correlated with heterochromatin and gene repression include methylation of H3K9, H3K27, and H4K20; ubiquitination of H2AK119; and sumoylation of H2AK126, H2BK6, and H2BK7.

Among these modifications, acetylation and methylation have been intensively studied. Histone acetyltransferases (HATs) transfer acetyl groups to lysine residues, resulting in gene activation, whereas histone deacetylases (HDACs) remove acetyl groups, resulting in gene silencing [65]. Histone methyltransferases (HMTs) transfer methyl groups, whereas histone demethylases (HDMs) remove methyl groups [66]. HMTs and HDMs specifically catalyze particular residues. The functions of histone methylation are affected by both the position of the residue and the number of methyl groups. According to the histone code hypothesis, multiple histone modifications, acting in a combinatorial or sequential
fashion on one or multiple histone tails, specify unique downstream functions [67]. A complex combination of these histone modifications is thought to regulate chromatin structure and gene transcription.

3.3. DNA Methylation. DNA methylation is a biochemical process in which a methyl group is added to a carbon 5’ position of a CpG dinucleotide and 5-methylcytosine (5mC) is generated [68]. This process occurs in regions of clustered CpG dinucleotides, known as CpG islands, which are typically located in the promoters of genes [69]. Approximately 70% of annotated gene promoters are correlated with CpG islands [70]. A high level of DNA methylation at CpG islands inhibits binding of TFs and represses gene transcription, whereas a low level is associated with an open chromatin structure and active gene transcription [71]. Although some CpG islands are located at a distance from promoters, they can also affect gene transcription [72].

The process of DNA methylation is catalyzed by DNA methyltransferases (DNMTs), including DNMT1, DNMT3a, and DNMT3b, which use S-adenosylmethionine (SAM) as the methyl donor [73]. DNMT1 maintains the DNA methylation patterns through cell replication [74]. Specifically, it is upregulated during the S phase of the cell cycle, is recruited to DNA replication forks, and methylates CpG sites on daughter strands. On the other hand, DNMT3a and DNMT3b are de novo methyltransferases and establish methylation patterns in both unmethylated and hemimethylated CpG sites with equal efficiencies [75].

Recent advances have revealed the process of active DNA demethylation by the ten-eleven translocation (TET) family of enzymes, including TET1, TET2, and TET3, which are α-ketoglutarate- and Fe(II)-dependent dioxygenases and catalyze the conversion of 5mC to 5-hydroxymethylcytosine (5hmC) [76]. It has been demonstrated that TET proteins contribute to the additional oxidation of 5hmC to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) [77]. An unmodified C is generated either through a replication-dependent dilution of 5hmC or through the removal of 5fC or 5caC by thymine DNA glycosylase-(TDG-) mediated base excision repair [78].

3.4. miRNAs. miRNAs are short noncoding RNAs that are 19–25 nucleotides long and cause posttranscriptional and posttranslational gene silencing [79]. The miRNA sequence is transcribed to long primary miRNA (pri-miRNA) of several kb in length that are capped and polyadenylated by RNA polymerase II and then processed by Drosha to form an approximately 70-nucleotide hairpin precursor miRNA (pre-miRNA) in the nucleus. The pre-miRNA is processed in the cytosol by RNAse III-type enzyme Dicer to a mature miRNA duplex of approximately 22 nucleotides. The double-stranded miRNA complex is associated with the RNA-induced silencing complex (RISC), which is composed of the transactivation-responsive RNA-binding protein (TRBP) and Argonaute (Ago2). After the complementary strand is removed from the RISC, functional miRNA binds to the 3’-untranslated region (UTR) of the messenger RNA (mRNA) of a target gene and causes mRNA cleavage or translational repression [80, 81]. Perfect binding between miRNA and the mRNA target results in the Ago-catalyzed cleavage of the mRNA strand, whereas imperfect binding leads to the repression of mRNA translation. Although to date approximately 1900 human miRNAs have been identified, most of their target genes remain unknown.

3.5. Chromatin Structure-Based Regulation of Gene Transcription. Epigenetic mechanisms regulate chromatin structure and the sustained and distinct patterns of gene expression through cell differentiation. Complex is the association between chromatin structure and gene transcription. Analyses of genome-wide profiles of histone methylation and gene expression have demonstrated a general correlation between histone methylation patterns and gene expression [82]. The levels of trimethylation at H3K4 (H3K4me3) and at H3K27 (H3K27me3) are positively and negatively correlated with gene expression, respectively. These correlations demonstrate four distinct states: repressed, active, poised, and bivalent [83, 84]. In the repressed state, the gene locus has a condensed chromatin structure and gene transcription is repressed. In the active state, the gene locus has an open chromatin structure and gene transcription is active. In the poised state, the gene locus has an open chromatin structure, similar to the active state, but there is no active gene transcription at resting. However, following activation, gene transcription can be rapidly activated. Genes in the bivalent state contain high levels of both active and repressive histone markers. The chromatin structure can change to an open or condensed state both through cell differentiation and upon activation. The specific epigenetic landscape provides the chromatin basis for distinct gene transcription.

4. Epigenetic Abnormalities in RASFs

4.1. Histone Modifications in RASFs. Aberrant histone modifications have been shown to be involved in the activation of RASFs (Table 1). An H3K27-specific HMT, enhancer of zeste homolog 2 (EZH2), was highly expressed in RASFs and induced by TNFα through nuclear factor-kappa B (NF-κB) and Jun kinase pathways [85]. Secreted fizzled-related protein 1 (SFRP1), an inhibitor of Wnt signaling, was identified as the target gene and was associated with the activation of RASFs. In addition, its expression was found to be associated with specific histone markers in the promoter, such as H3K4me3 and H3K27me3. T-box transcription factor 5 (TBX5) is highly expressed in RASFs [86]. Correspondingly, active histone markers, including H3K4me3 and histone acetylation, were increased in the TBX5 promoter of RASFs. Overexpression of TBX5 altered expression of 790 genes, including IL-8, C-X-C motif ligand 12 (CXCL12), and C-C motif ligand 20 (CCL20). It has been suggested that TBX5 is newly identified as an inducer of important chemokines in RASFs. MMP-1, MMP-3, MMP-9, and MMP-13, which have pivotal roles in the pathogenesis of RA, are highly expressed in RASFs [87]. Accordingly, the levels of H3K4me3 increased, whereas those of H3K27me3 decreased in the MMP promoters in RASFs. WD (tryptophan-aspartate) repeat domain 5 (WDR5) is a core subunit of complex proteins associated with

Journal of Immunology Research
### Table 1: Abnormality of histone modifications in RASFs.

| Epigenetic alterations | Function | References |
|------------------------|----------|------------|
| Increase of H3K27me3 by upregulated EZH2 | Decrease of SFRP1 involved in Wnt signaling inhibition | [85] |
| Increase of H3K4me3, decrease of H3K27me3, and increase of H3ac | Increase of TBX5 involved in chemokine production | [86] |
| Increase of H3K4me3 and decrease of H3K27me3 | Increase of MMP-1, MMP-3, MMP-9, and MMP-13 involved in extracellular matrix degradation | [87] |
| Increase of H3ac | Increase of IL-6 involved in inflammation | [88] |
| Decrease of HDAC activity and expression | Histone hyperacetylation | [89] |
| Increase of HDAC activity and expression | Histone hypoacetylation | [90] |

### Table 2: Abnormality of DNA methylation in RASFs.

| Epigenetic alterations | Function | References |
|------------------------|----------|------------|
| Global genomic hypomethylation and decrease of DNMT1 protein expression | Increase of 186 gene expressions | [93] |
| Normal DNMT1 gene expression | Decrease of DNMT1 gene expression after IL-1 stimulation | [94] |
| Hypermethylation | Decrease of DR3 involved in resistance to apoptosis | [95] |
| Hypomethylation | Increase of TBX5 involved in chemokine production | [86] |
| Hypomethylation | Increase of CXCL12 involved in inflammation | [96] |
| Genome-wide differential methylation | 1859 differentially methylated loci | [97] |
| Genome-wide differential methylation | 2375 differentially methylated loci | [98] |

SET1 (COMPASS) or COMPASS-like complexes that catalyze H3K4 methylation, which is necessary for the generation of H3K4me3. WDR5 knockdown reduced H3K4me3 as well as the expression of MMP-1, MMP-3, MMP-9, and MMP-13 in RASFs. IL-6 and soluble IL-6 receptor α (sIL-6Rα) increased the expression of MMP-1, MMP-3, and MMP-13, but not MMP-9. IL-6-induced transcription factor signal transducer and activator of transcription 3 (STAT3) were found to bind to the MMP-1, MMP-3, and MMP-13 promoters, but not the MMP-9 promoter. High expression of IL-6 was associated with high levels of acetylation at H3 (H3ac) in the IL-6 promoter in RASFs [88]. Curcumin, a HAT inhibitor, decreased IL-6 expression and the level of H3ac in the IL-6 promoter in RASFs. Huber et al. reported that nuclear HDAC activity was low in RA synovial tissues, whereas nuclear HAT activity was similar in RA and osteoarthritis (OA) synovial tissues [89]. Expression of HDAC1 and HDAC2 was repressed in RA synovial tissues. It is suggested that the balance between HAT and HDAC activities shifted to histone hyperacetylation in RA. On the other hand, Kawabata et al. showed that nuclear HDAC activity increased in RA synovial tissues and was associated with the amount of cytoplasmic TNFα [90]. HDAC1 is highly expressed in RA synovial tissues, and its activity and expression are upregulated after TNFα stimulation. In view of conflicting data on the roles of histone acetylation-catalyzing enzymes in RA, additional studies are thought to be needed. IL-6 and IL-8 expression was reduced in RA synovial tissues by HDAC inhibitors (HDACi), including trichostatin A (TSA), sodium phenylbutyrate, and nicotinamide [91]. In addition, HDACi, such as TSA and givinostat, repressed IL-6 production that was induced by IL-1β, TNFα, and Toll-like receptor (TLR) ligands and also decreased the stability of IL-6 mRNA in RASFs [92].

### 4.2 DNA Methylation in RASFs.

Several reports have suggested the contribution of DNA methylation to the pathogenesis of RA, and a variety of altered DNA methylation patterns have been described in RASFs (Table 2). Global genomic DNA hypomethylation was seen in RA synovial tissues [93]. Proliferating RASFs were deficient in DNMT1 and 5-azacytidine (5-azaC), an inhibitor of DNMTs, provided normal SFs with the activated phenotype of RASFs. DNA hypomethylation upregulated expression of 186 genes, including growth factors/receptors, extracellular matrix proteins, adhesion molecules, and matrix-degrading enzymes. In spite of similar levels of DNMT1 transcripts between RASFs and OASFs [94], DNMT1 protein expression is reduced in RASFs, in particular upon stimulation with cytokines or growth factors [93]. In addition, IL-1 stimulation decreases DNMT1 transcription. Death receptor 3 (DR3) is a member of the apoptosis-inducing Fas gene family. Enforced hypermethylation of the CpG island repressed DR3 gene expression, which resulted in resistance to apoptosis in RASFs [95]. Differentially methylated genes between RASFs and OASFs were examined by methylated DNA immunoprecipitation and promoter tiling assays, which showed that TBX5 is less methylated in RASFs than in OASFs [86]. TBX5 induces the production of chemokines, such as IL-8, CXCL12, and CCL20. Basal expression of CXCL12 was high in RASFs and low CpG methylation was found in the CXCL12 promoter of RASFs [96]. 5-azaC increased CXCL12 expression and decreased the methylation of CpG nucleotides.
in the CXCL12 promoter of RASFs. Furthermore, genome-wide analyses of DNA methylation loci in RASFs were performed. Nakano et al. reported 1859 differentially methylated loci [97]. Some of hypomethylated loci were key genes in the pathogenesis of RA, including CHISL1, CASP1, STAT3, MAP3K5, MEFV, and WISP3. TGFBR2 and FOXO1 were identified as hypermethylated loci. Pathway analysis showed that hypomethylated genes were related to cell migration, cell adhesion, transendothelial migration, and extracellular matrix interactions. Whitaker et al. determined whether DNA methylation signatures change in long-term cultured RASFs [98]. The genome-wide patterns of differential DNA methylation of RASFs were examined at passages 3, 5, and 7 and were quite similar regardless of passage number. By analyses of pathway and ontology databases, differentially methylated genes were associated with innate immunity, cell adhesion, and cytokines.

4.3. miRNAs in RASFs. Several miRNAs are associated with the pathogenesis of RA (Table 3). For example, the basal expression level of miR-34a* is repressed in RASFs [99]. The promoter of miR-34a* is methylated and the transcription of miR-34a* increases upon treatment with 5-azaC. X-linked inhibitor of apoptosis protein (XIAP) was identified as a direct target of miR-34a*. XIAP blocks apoptosis by direct binding to caspasps. Enforced expression of miR-34a* caused Fas ligand-(FasL-) and TNF-related apoptosis-inducing ligand-(TRAIL-) mediated apoptosis in RASFs. Downregulation of proapoptotic miR-34a* resulted in upregulation of XIAP, thereby contributing to the resistance of RASFs to apoptosis. Alterations in the expression of miRNAs in RASFs were examined by screening 260 miRNAs [100]. The expression of miR-203 was high in RASFs, and 5-azaC inhibited MMP-3 expression and repressed the induction of MMP-1 and MMP-3 by TLR ligands and cytokines. In another study, differentially expressed miRNAs in RASFs were screened by microarray analysis, which showed that miR-155 expression was also upregulated and induced by TNFα in RASFs [102]. Enforced expression of miR-155 reduced MMP-3 expression and inhibited the proliferation and invasion of RASFs. Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase epsilon (IKBKE), is a target of miR-155, and it has been suggested that miR-155 may be a protective factor against inflammation by attenuating expression of IKBKE in RASFs. miR-22 directly targeted the 3′-UTR of Cysteine-rich angiogenic inducer 61 (CYR61) mRNA and repressed CYR61 expression [103]. CYR61 promotes RASF proliferation and differentiation of T helper 17 (Th17) cells that play an important role in the pathogenesis of RA. Expression of miR-22 was reduced and was negatively correlated with CYR61 expression in RASFs. Wild-type p53 induced miR-22 transcription by binding to the promoter of the miR-22 gene, whereas the mutant forms of p53 that were frequently observed in RASFs suppressed miR-22 expression. Stimulation of RASFs with LPS and BLP decreased miR-20a expression [104]. This decrease was associated with upregulation of apoptosis signal-regulating kinase (ASK) 1 that was a key component of the TLR4 pathway. ASK1 is a direct target of miR-20a. Overexpression of miR-20a decreased ASK1 expression in LPS- and BLP-activated RASFs. MicroRNA microarray analysis demonstrated that miR-19b was downregulated in RASFs [105]. miR-19b targets TLR2 mRNA and overexpression of miR-19b decreases expression of TLR2 and IL-6, and MMP-3. It is thought that miR-19b can act as a negative regulator of inflammation in RA.

5. Conclusion

Increasing evidence has shown that aberrant epigenetic changes contribute to the development of RA and affect disease susceptibility and severity in RA. Further study is needed to reveal the crosstalk among these different epigenetic mechanisms in different cell types in RA. Synoviocytes are comprised of fibroblasts and macrophages, and not only SFs but also synovial macrophages are involved in inflammation of the RA synovium. Therefore, it will be important to investigate the relationship between SFs and synovial
macrophages in RA, including how they can influence each other by epigenetic mechanisms. It is hoped that advances in the studies of the epigenetic mechanisms in RA will provide a better understanding of the pathogenesis of RA and help develop new therapeutic strategies and biomarkers for RA.

Competing Interests
The authors have no conflicting financial interests.

Acknowledgments
This work was supported by JSPS KAKENHI Grant nos. 16K09903 (to Dr. Araki) and 16K09902 (to Dr. Mimura), by Grant-in Aid for Young researchers from Saitama Medical University Hospital (27-E-1-03) (to Dr. Araki), and by the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED) (15ek0109019h0002) (to Dr. Mimura).

References
[1] G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003.
[2] A. Gibofsky, “Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis,” American Journal of Managed Care, vol. 20, S7, pp. S128–S135, 2014.
[3] L. I. Sakkas, D. P. Bogdanos, C. Katsiari, and C. D. Platoucas, “Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment,” Autoimmunity Reviews, vol. 13, no. 11, pp. II14–II20, 2014.
[4] B. György, E. Tóth, E. Tarcsa, A. Falus, and E. I. Buzás, “Citrullination: a posttranslational modification in health and disease,” International Journal of Biochemistry and Cell Biology, vol. 38, no. 10, pp. 1662–1677, 2006.
[5] B. I. J. Young, R. K. Mallya, R. D. Leslie, C. J. Clark, and T. J. Hamblin, “Anti-keratin antibodies in rheumatoid arthritis,” British Medical Journal, vol. 2, no. 6182, pp. 97–99, 1979.
[6] E. Girbal-Neuhauser, J.-J. Durieux, M. Arnaud et al., “The epitopes targeted by the rheumatoid arthritis-associated anti-filaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deamination of arginine residues,” The Journal of Immunology, vol. 162, no. 1, pp. 585–594, 1999.
[7] M. Sebbag, N. Moinard, I. Auger et al., “Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins,” European Journal of Immunology, vol. 36, no. 8, pp. 2250–2263, 2006.
[8] E. R. Vossenaar, N. Despré, E. Lapointe et al., “Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin,” Arthritis Research & Therapy, vol. 6, no. 2, pp. R142–150, 2004.
[9] H. Burkhardt, B. Sehnert, R. Bockermann, A. Engström, J. R. Kalden, and R. Holmdahl, “Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis,” European Journal of Immunology, vol. 35, no. 5, pp. 1643–1652, 2005.
[10] M. M. Souto-Carneiro, H. Burkhardt, E. C. Müller et al., “Human monoclonal rheumatoid synovial B lymphocyte hybridoma with a new disease-related specificity for cartilage oligomeric matrix protein,” Journal of Immunology, vol. 166, no. 6, pp. 4202–4208, 2001.
[11] K. Lundberg, A. Kinloch, B. A. Fisher et al., “Antibodies to citrullinated α-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase,” Arthritis and Rheumatism, vol. 58, no. 10, pp. 3009–3019, 2008.
[12] W. V. Eden, J. E. R. Tholet, R. V. D. Zee et al., “Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis,” Nature, vol. 331, no. 6152, pp. 171–173, 1988.
[13] J. K. Gorgonzy, P. Bartz-Bazzanella, W. Hu, M. C. Jendro, D. R. Walser-Kuntz, and C. M. Weyand, “Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis,” The Journal of Clinical Investigation, vol. 94, no. 5, pp. 2068–2076, 1994.
[14] I. Waase, C. Kayser, P. J. Carlson, J. J. Gorgonzy, and C. M. Weyand, “Oligoclonal T cell proliferation in patients with rheumatoid arthritis and their unaffected siblings,” Arthritis and Rheumatism, vol. 39, no. 6, pp. 904–913, 1996.
[15] I. A. Udalova, A. Mantovani, and M. Feldmann, “Macrophage heterogeneity in the context of rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 12, no. 8, pp. 472–485, 2016.
[16] R. R. Hardy, K. Hayakawa, M. Shimizu, K. Yamasaki, and T. Kishimoto, “Rheumatoid factor secretion from human Leu-1+ B cells,” Science, vol. 236, no. 4797, pp. 81–83, 1987.
[17] E. M. Tan and J. S. Smolen, “Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor,” The Journal of Experimental Medicine, vol. 213, no. 10, pp. 1937–1950, 2016.
[18] L. Perez, J. Orte, and J. A. Brieva, "Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10," Arthritis and Rheumatism, vol. 38, no. 12, pp. 1771–1776, 1995.
[19] E. H. S. Choy and G. S. Panayi, “Cytokine pathways and joint inflammation in rheumatoid arthritis,” New England Journal of Medicine, vol. 344, no. 12, pp. 907–916, 2001.
[20] E. H. Noss and M. B. Brenner, “The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis,” Immunological Reviews, vol. 223, no. 1, pp. 252–270, 2008.
[21] A. Filer, “The fibroblast as a therapeutic target in rheumatoid arthritis,” Current Opinion in Pharmacology, vol. 13, no. 3, pp. 413–419, 2013.
[22] I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011.
[23] C. L. Kohem, R. I. Brezinschek, H. Wisbey, C. Tortorella, P. E. Lipsky, and N. Oppenheimer-Marks, “Enrichment of differentiated CD45RBdim,CD27- memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 39, no. 5, pp. 844–854, 1996.
[24] T. Nanki, K. Hayashida, H. S. El-Gabalawy et al., “Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium,” Journal of Immunology, vol. 165, no. 11, pp. 6590–6598, 2000.
[25] M. Natsumeda, K. Nishiya, and Z. Ota, “Stimulation by interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 42, no. 7, pp. 1508–1516, 1999.
K.G.Saag,J.R.Cerhan,S.Kolluri,K.Ohashi,G.W.Hunninghake,K. Klein, C. Ospelt, and S. Gay, "Epigenetic contributions in rheumatoid arthritis," Arthritis and Rheumatism, vol. 43, no. 11, pp. 2523–2530, 2000.

K. H. Costenbader, S. Gay, M. E. Alarcón-Riquelme, L. Iacopino, and A. Doria, "Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?" Autoimmunity Reviews, vol. II, no. 8, pp. 604–609, 2012.

K. Klein, C. Ospelt, and S. Gay, "Epigenetic contributions in the development of rheumatoid arthritis," Arthritis Research and Therapy, vol. 14, no. 6, article 227, 2012.

K. Aho, M. Koskenvuo, J. Tuominen, and J. Kaprio, "Occurrence of rheumatoid arthritis in a nationwide series of twins," Journal of Rheumatology, vol. 13, no. 5, pp. 899–902, 1986.

A. J. Silman, A. J. MacGregor, W. Thomson et al., "Twin concordance rates for rheumatoid arthritis: results from a nationwide study," British Journal of Rheumatology, vol. 32, no. 10, pp. 903–907, 1993.

A. I. MacGregor, H. Snieder, A. S. Rigby et al., "Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins," Arthritis and Rheumatism, vol. 43, no. 1, pp. 30–37, 2000.

K. Hemminki, X. Li, J. Sundquist, and K. Sundquist, "Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions," Arthritis and Rheumatism, vol. 60, no. 3, pp. 661–668, 2009.

P. K. Gregersen, J. Silver, and R. J. Winchester, "The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis," Arthritis and Rheumatism, vol. 30, no. 11, pp. 1205–1213, 1987.

M.A. Gonzalez-Gay, C. Garcia-Porrua, and A. H. Hajeer, "Influence of human leukocyte antigen-DRBI on the susceptibility and severity of rheumatoid arthritis," Seminars in Arthritis and Rheumatism, vol. 31, no. 6, pp. 355–360, 2002.

F. A. Van Gaalen, J. Van Aken, T. W. J. Huizinga et al., "Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis," Arthritis and Rheumatism, vol. 50, no. 7, pp. 2113–2121, 2004.

Y. Okada, D. Wu, G. Trynka et al., "Genetics of rheumatoid arthritis contributes to biology and drug discovery," Nature, vol. 506, no. 7488, pp. 376–381, 2014.

K. Yamamoto, Y. Okada, A. Suzuki, and Y. Kochi, "Genetic studies of rheumatoid arthritis," Proceedings of the Japan Academy, Series B, vol. 91, no. 8, pp. 410–422, 2015.

K. G. Saag, J. R. Cerhan, S. Kolluri, K. Ohashi, G. W. Hunninghake, and D. A. Schwartz, "Cigarette smoking and rheumatoid arthritis severity," Annals of the Rheumatic Diseases, vol. 56, no. 8, pp. 463–469, 1997.

D. Hutchinson, L. Shepstone, R. Moots, J. T. Lear, and M. P. Lynch, "Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA," Annals of the Rheumatic Diseases, vol. 60, no. 3, pp. 223–227, 2001.

K. Lundberg, N. Wegner, T. Yuel-Lindberg, and P. J. Venables, "Periodontitis in RA-the citrullinated enolase connection," Nature Reviews Rheumatology, vol. 6, no. 12, pp. 727–730, 2010.

E. D. Rosenstein, R. A. Greenwald, L. J. Kushner, and G. Weissmann, "Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis," Inflammation, vol. 28, no. 6, pp. 311–318, 2004.

D. Makrygiannakis, M. Hermansson, A.-K. Ulfgren et al., "Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells," Annals of the Rheumatic Diseases, vol. 67, no. 10, pp. 1488–1492, 2008.

D. Damgaard, M. Friberg Bruun Nielsen, M. Q. Gausbaek, Y. Palarasah, V. Svané-Knudsen, and C. H. Nielsen, "Smoking is associated with increased levels of extracellular peptidylarginine deiminase 2 (PADD2) in the lungs," Clinical and Experimental Rheumatology, vol. 33, no. 3, pp. 405–408, 2015.

K. H. Costenbader and E. W. Karlson, "Einstein-Barr virus and rheumatoid arthritis: is there a link?" Arthritis Research & Therapy, vol. 8, no. 1, article 204, 2006.

M. A. Aslpaugh and E. M. Tan, "Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence," Arthritis and Rheumatism, vol. 19, no. 4, pp. 711–719, 1976.

M. A. Aslpaugh, F. C. Jensen, H. Rabin, and E. M. Tan, "Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis," Journal of Experimental Medicine, vol. 147, no. 4, pp. 1018–1027, 1978.

N. Balandraud, J. B. Meynard, I. Auger et al., "Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction," Arthritis and Rheumatism, vol. 48, no. 5, pp. 1223–1228, 2003.

M. M. Newkirk, K. N. Watanabe Duffy, J. Leclerc, N. Lambert, and J. B. Shiroya, "Detection of cytomegalovirus, Epstein-barr virus and herpes virus-6 in patients with rheumatoid arthritis with or without Sjögren's syndrome," Rheumatology, vol. 33, no. 4, pp. 317–322, 1994.

T. Takeda, Y. Mizugaki, L. Matsubara, S. Imai, T. Koike, and K. Takada, "Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis," Arthritis and Rheumatism, vol. 43, no. 6, pp. 1218–1225, 2000.

G. Tosato, A. D. Steinberg, R. Yarcheo et al., "Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis," Journal of Clinical Investigation, vol. 73, no. 6, pp. 1789–1795, 1984.

P. A. Bardwick, H. G. Bluestein, N. J. Zvaifler, J. M. Depper, and J. E. Seegmiller, "Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells," Arthritis and Rheumatism, vol. 23, no. 6, pp. 626–632, 1980.

M. Cutolo and S. Accardo, "Sex hormones, HLA and rheumatoid arthritis," Clinical and Experimental Rheumatology, vol 9, no. 6, pp. 641–646, 1991.

M. Cutolo, B. Villaggio, C. Cravìoto, C. Pizzorni, B. Seriolo, and A. Sulli, "Sex hormones and rheumatoid arthritis," Autoimmunity Reviews, vol. 1, no. 5, pp. 284–289, 2002.

M. T. Cantorna, C. E. Hayes, and H. F. DeLuca, "1,25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis," Journal of Nutrition, vol. 128, no. 1, pp. 68–72, 1998.

L. A. Merlino, J. Curtis, T. R. Mikuls, J. R. Cerhan, L. A. Criswell, and K. G. Saag, "Vitamin D intake is inversely associated with
rheumatoid arthritis: results from the Iowa Women’s Health Study,” *Arthritis and Rheumatism*, vol. 50, no. 1, pp. 72–77, 2004.

[58] P. Stolt, H. Källberg, I. Lundberg, B. Sjögren, L. Klareskog, and L. Alfredsson, “Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study,” *Annals of the Rheumatic Diseases*, vol. 64, no. 4, pp. 582–586, 2005.

[59] S. L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard, “An operational definition of epigenetics,” *Genes and Development*, vol. 23, no. 7, pp. 781–783, 2009.

[60] A. Bassett, S. Cooper, C. Wu, and A. Travers, “The folding and unfolding of eukaryotic chromatin,” *Current Opinion in Genetics and Development*, vol. 19, no. 2, pp. 159–165, 2009.

[61] S. Golbabapour, M. A. Abdulla, and M. Hajrezaei, “A concise review on epigenetic regulation: insight into molecular mechanisms,” *International Journal of Molecular Sciences*, vol. 12, no. 12, pp. 8661–8694, 2011.

[62] B. Li, M. Carey, and J. L. Workman, “The role of chromatin during transcription,” *Cell*, vol. 128, no. 4, pp. 707–719, 2007.

[63] S. L. Berger, “The complex language of chromatin regulation during transcription,” *Nature*, vol. 447, no. 7143, pp. 407–412, 2007.

[64] T. Kouzarides, “Chromatin modifications and their function,” *Cell*, vol. 128, no. 4, pp. 693–705, 2007.

[65] M.-H. Kuo and C. D. Allis, “Roles of histone acetyltransferases and deacetylases in gene regulation,” *BioEssays*, vol. 20, no. 8, pp. 615–626, 1998.

[66] E. L. Greer and Y. Shi, “Histone methylation: a dynamic mark in health, disease and inheritance,” *Nature Reviews Genetics*, vol. 13, no. 5, pp. 343–357, 2012.

[67] B. D. Strahl and C. D. Allis, “The language of covalent histone modifications,” *Nature*, vol. 403, no. 6765, pp. 41–45, 2000.

[68] Z. D. Smith and A. Meissner, “DNA methylation: roles in mammalian development,” *Nature Reviews Genetics*, vol. 14, no. 3, pp. 204–220, 2013.

[69] A. M. Deaton and A. Bird, “CpG islands and the regulation of transcription,” *Genes and Development*, vol. 25, no. 10, pp. 1010–1022, 2011.

[70] S. Saxonov, P. Berg, and D. L. Brutlag, “A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 5, pp. 1412–1417, 2006.

[71] S. Eden and H. Cedar, “Role of DNA methylation in the regulation of transcription,” *Current Opinion in Genetics and Development*, vol. 4, no. 2, pp. 255–259, 1994.

[72] A. K. Maunakea, R. P. Nagarajan, M. Bilenky et al., “Conserved role of intragenic DNA methylation in regulating alternative promoters,” *Nature*, vol. 466, no. 7303, pp. 253–257, 2010.

[73] P. K. Chiang, R. K. Gordon, J. Tal et al., “S-adenosylmethionine and methylation,” *FASEB Journal*, vol. 10, no. 4, pp. 471–480, 1996.

[74] S. Pradhan and P.-O. Esteve, “Mammalian DNA (cytosine-5) methyltransferases and their expression,” *Clinical Immunology*, vol. 109, no. 1, pp. 16–16, 2003.

[75] M. Okano, D. W. Bell, D. A. Haber, and E. Li, “DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development,” *Cell*, vol. 99, no. 3, pp. 247–257, 1999.

[76] M. Tählini, K. P. Koh, Y. Shen et al., “Conversion of 5-methylcytosine to 3-hydroxymethylcytosine in mammalian DNA by MLL partner TET1,” *Science*, vol. 324, no. 5929, pp. 930–935, 2009.

[77] L. Shen, C.-X. Song, C. He, and Y. Zhang, “Mechanism and function of oxidative reversal of DNA and RNA methylation,” *Annual Review of Biochemistry*, vol. 83, pp. 585–614, 2014.

[78] R. M. Kohli and Y. Zhang, “TET enzymes, TDG and the dynamics of DNA demethylation,” *Nature*, vol. 502, no. 7472, pp. 472–479, 2013.

[79] M. R. Fabian, N. Sonenberg, and W. Filipowicz, “Regulation of mRNA translation and stability by microRNAs,” *Annual Review of Biochemistry*, vol. 79, pp. 351–379, 2010.

[80] L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” *Nature Reviews Genetics*, vol. 5, no. 7, pp. 522–531, 2004.

[81] D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” *Cell*, vol. 136, no. 2, pp. 215–233, 2009.

[82] Y. Araki, Z. Wang, C. Zang et al., “Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells,” *Immunity*, vol. 30, no. 6, pp. 912–925, 2009.

[83] Y. Araki, M. Fann, R. Wersto, and N.-P. Weng, “Histone acetylation facilitates rapid and robust memory CD8 T Cell response through differential expression of effector molecules (comesor- dermin and its targets: perforin and granzyme B),” *The Journal of Immunology*, vol. 180, no. 12, pp. 8102–8108, 2008.

[84] N.-P. Weng, Y. Araki, and K. Subedi, “The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation,” *Nature Reviews Immunology*, vol. 12, no. 4, pp. 306–315, 2012.

[85] M. Trenkmann, M. Brock, R. E. Gay et al., “Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 70, no. 8, pp. 1482–1488, 2011.

[86] E. Karouzakis, M. Trenkmann, R. E. Gay, B. A. Michel, S. Gay, and M. Neidhart, “Epigenome analysis reveals TBX5 as a novel transcription factor involved in the activation of rheumatoid arthritis synovial fibroblasts,” *Journal of Immunology*, vol. 193, no. 10, pp. 4945–4951, 2014.

[87] Y. Araki, T. Tsuzuki Wada, Y. Aizaki et al., “Histone methylation and STAT-3 differentially regulate interleukin-6-induced matrix metalloproteinase gene activation in rheumatoid arthritis synovial fibroblasts,” *Arthritis & Rheumatology*, vol. 68, no. 5, pp. 1111–1123, 2016.

[88] T. T. Wada, Y. Araki, K. Sato et al., “Abrerrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts,” *Biochemical and Biophysical Research Communications*, vol. 444, no. 4, pp. 682–686, 2014.

[89] L. C. Huber, M. Brock, H. Hemmatatad et al., “Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients,” *Arthritis and Rheumatism*, vol. 56, no. 4, pp. 1087–1093, 2007.

[90] T. Kawabata, K. Nishida, K. Takasugi et al., “Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis,” *Arthritis Research and Therapy*, vol. 12, no. 4, article no. R133, 2010.

[91] A. M. Grabiec, S. Krausz, W. De Jager et al., “Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue,” *Journal of Immunology*, vol. 184, no. 5, pp. 2718–2728, 2010.
A. M. Grabiec, O. Korchynskyi, P. P. Tak, and K. A. Reedquist, "Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay," *Annals of the Rheumatic Diseases*, vol. 71, no. 3, pp. 424–431, 2012.

E. Karouzakis, R. E. Gay, B. A. Michel, S. Gay, and M. Neidhart, "DNA hypomethylation in rheumatoid arthritis synovial fibroblasts," *Arthritis and Rheumatism*, vol. 60, no. 12, pp. 3613–3622, 2009.

K. Nakano, D. L. Boyle, and G. S. Firestein, "Regulation of DNA methylation in rheumatoid arthritis synoviocytes," *Journal of Immunology*, vol. 190, no. 3, pp. 1297–1303, 2013.

N. Takami, K. Osawa, Y. Miura et al., "Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells," *Arthritis and Rheumatism*, vol. 54, no. 3, pp. 779–787, 2006.

E. Karouzakis, Y. Rengel, A. Jüngel et al., "DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts," *Genes and Immunity*, vol. 12, no. 8, pp. 643–652, 2011.

K. Nakano, J. W. Whitaker, D. L. Boyle, W. Wang, and G. S. Firestein, "DNA methylome signature in rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 72, no. 1, pp. 110–117, 2013.

J. W. Whitaker, R. Shoemaker, D. L. Boyle et al., "An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype," *Genome Medicine*, vol. 5, no. 4, article 40, 2013.

F. Niederer, M. Trenkmann, C. Ospelt et al., "Down-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance," *Arthritis and Rheumatism*, vol. 64, no. 6, pp. 1771–1779, 2012.

J. Stanczyk, C. Ospelt, E. Karouzakis et al., "Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation," *Arthritis and Rheumatism*, vol. 63, no. 2, pp. 373–381, 2011.

J. Stanczyk, D. M. Leslie Pedrioli, F. Brentano et al., "Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis," *Arthritis and Rheumatism*, vol. 58, no. 4, pp. 1001–1009, 2008.

L. Long, P. Yu, Y. Liu et al., "Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis," *Clinical and Developmental Immunology*, vol. 2013, Article ID 296139, 10 pages, 2013.

J. Lin, R. Huo, L. Xiao et al., "A novel p53/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis," *Arthritis and Rheumatology*, vol. 66, no. 1, pp. 49–59, 2014.

L. Philippe, G. Alsaleh, A. Pichot et al., "MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes," *Annals of the Rheumatic Diseases*, vol. 72, no. 6, pp. 1071–1079, 2013.

L. Philippe, G. Alsaleh, G. Suffert et al., "TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes," *Journal of Immunology*, vol. 188, no. 1, pp. 454–461, 2012.